GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » ROC %

Sunesis Pharmaceuticals (FRA:RYIS) ROC % : -1,003.43% (As of Dec. 2020)


View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Sunesis Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Dec. 2020 was -1,003.43%.

As of today (2024-05-25), Sunesis Pharmaceuticals's WACC % is 0.00%. Sunesis Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Sunesis Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Sunesis Pharmaceuticals ROC % Historical Data

The historical data trend for Sunesis Pharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals ROC % Chart

Sunesis Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -417.52 -411.81 -283.78 -285.78 -386.04

Sunesis Pharmaceuticals Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -261.99 -298.74 -337.64 -380.37 -1,003.43

Sunesis Pharmaceuticals ROC % Calculation

Sunesis Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2020 is calculated as:

ROC % (A: Dec. 2020 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2019 ) + Invested Capital (A: Dec. 2020 ))/ count )
=-18.333 * ( 1 - 0% )/( (7.229 + 2.269)/ 2 )
=-18.333/4.749
=-386.04 %

where

Sunesis Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2020 is calculated as:

ROC % (Q: Dec. 2020 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2020 ) + Invested Capital (Q: Dec. 2020 ))/ count )
=-18.704 * ( 1 - 0% )/( (1.459 + 2.269)/ 2 )
=-18.704/1.864
=-1,003.43 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2020) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunesis Pharmaceuticals  (FRA:RYIS) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Sunesis Pharmaceuticals's WACC % is 0.00%. Sunesis Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Sunesis Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Sunesis Pharmaceuticals ROC % Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Traded in Other Exchanges
N/A
Address
395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines